Johannes Müller

发表

Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies

A. Haberland, H. Weisshoff, A. Dallmann, 2021, Viruses.

Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins

A. Haberland, H. Weisshoff, A. Dallmann, 2020, Heliyon.

Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection

T. Harrer, G. Wallukat, U. Schlötzer-Schrehardt, 2021, Frontiers in Medicine.

Effects of the Tryptase Receptor Activating Peptide and Antibodies Against the Tryptase Receptor Par-2 on Neonatal Rat Cardiomyocytes in Culture

G. Wallukat, E. Nissen, F. Luft, 2003 .

Cardiomyopathy - An approach to the autoimmune background.

G. Wallukat, I. Schimke, P. Göttel, 2017, Autoimmunity reviews.

Agonistic Anti-b 1-Adrenergic Receptor Autoantibodies From Cardiomyopathy Patients Reduce the b 1-Adrenergic Receptor Expression in Neonatal Rat Cardiomyocytes

G. Wallukat, S. Podlowski, Johannes Müller, 1998 .

Agonistic Anti-β1-Adrenergic Receptor Autoantibodies From Cardiomyopathy Patients Reduce the β1-Adrenergic Receptor Expression in Neonatal Rat Cardiomyocytes

G. Wallukat, S. Podlowski, Johannes Müller, 1998 .

Adrenergic Receptor Expression in Neonatal Rat Cardiomyocytes 1 β Reduce the-Adrenergic Receptor Autoantibodies From Cardiomyopathy Patients 1 β Agonistic

G. Wallukat, S. Podlowski, Johannes Müller, 1998 .

Doberman pinschers present autoimmunity associated with functional autoantibodies: A model to study the autoimmune background of human dilated cardiomyopathy

G. Wallukat, I. Schimke, Johannes Müller, 2019, bioRxiv.

Autoantibodies against the Beta- and Muscarinic Receptors in Cardiomyopathy

G. Wallukat, E. Nissen, Johannes Müller, 2000, Herz.

Lack of efficacy of mono‐mode of action therapeutics in COVID‐19 therapy ‐ How the lack of predictive power of preclinical cell and animal studies leads developments astray

A. Haberland, Johannes Müller, 2021, Chemical biology & drug design.

Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms

G. Wallukat, B. Hohberger, Johannes Müller, 2021, Journal of Translational Autoimmunity.

Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors.

G. Wallukat, P. Luppa, A. Haberland, 2016, European journal of pharmacology.

Determination of Agonistically Acting Autoantibodies to the Adrenergic Beta-1 Receptor by Cellular Bioassay.

A. Haberland, Johannes Müller, S. Bartel, 2018, Methods in molecular biology.

Autoantibodies Directed Against the Endothelin A Receptor in Patients With Benign Prostatic Hyperplasia

G. Wallukat, R. Kunze, B. Jandrig, 2017, The Prostate.

Autoantibodies directed against α1-adrenergic receptor and endothelin receptor A in patients with prostate cancer

G. Wallukat, B. Jandrig, M. Schostak, 2020, Auto- immunity highlights.

Functional antibodies against G-protein coupled receptors in Beagle dogs infected with two different strains of Trypanosoma cruzi

G. Wallukat, M. O. Rocha, A. Talvani, 2022, Frontiers in Immunology.

Difference between beta1-adrenoceptor autoantibodies of human and animal origin—Limitations detecting beta1-adrenoceptor autoantibodies using peptide based ELISA technology

G. Wallukat, A. Haberland, Johannes Müller, 2018, PloS one.

Performance and in-house validation of a bioassay for the determination of beta1-autoantibodies found in patients with cardiomyopathy

G. Wallukat, A. Haberland, Johannes Müller, 2017, Heliyon.

Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats

G. Wallukat, E. Salzsieder, R. Kreutz, 2014, Molecular and Cellular Biochemistry.

The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes

G. Wallukat, I. Schimke, Johannes Müller, 2020, ESC heart failure.

Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling—Additional Information About TLR9 Involvement

A. Haberland, Johannes Müller, K. Wenzel, 2019, Cardiovascular Drugs and Therapy.

Functional autoantibodies in patients with different forms of dementia

G. Wallukat, H. Prüss, I. Schimke, 2018, PloS one.

High throughput bioassay for beta1-adrenoceptor autoantibody detection.

G. Wallukat, Ted Choi, A. Haberland, 2016, International journal of cardiology.

Overexpression of p16INK4a in Urothelial Carcinoma In Situ Is a Marker for MAPK-Mediated Epithelial-Mesenchymal Transition but Is Not Related to Human Papillomavirus Infection

M. Cronauer, M. Schrader, A. Schrader, 2013, PloS one.

In-Vivo Degradation of DNA-Based Therapeutic BC 007 in Humans

A. Haberland, H. Weisshoff, M. Grossmann, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Inducible nitric oxide synthase in the myocard

G. Wallukat, P. Karczewski, E. Krause, 2004, Molecular and Cellular Biochemistry.

Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance

G. Wallukat, C. Mardin, H. Prüss, 2022, bioRxiv.

Antigen-free control wells in an ELISA set-up for the determination of autoantibodies against G protein-coupled receptors—a requisite for correct data evaluation

G. Wallukat, A. Haberland, Johannes Müller, 2018, Analytical and Bioanalytical Chemistry.

Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies.

Eckhard Salzsieder, Ingolf Schimke, G. Wallukat, 2016, Atherosclerosis.

A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects

G. Wallukat, A. Haberland, G. Golor, 2020, Clinical Drug Investigation.

Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy.

M. Dathe, G. Srivatsa, A. Haberland, 2018, Journal of pharmaceutical sciences.